 "Cipla's Goa manufacturing plant")
Russia’s National Immunobiological Company (Nacimbio) has entered into an alliance with Cipla Limited for innovative antiviral medical products for HIV & hepatitis C treatment and technology transfer & active pharmaceutical ingredients (API) manufacturing. Nacimbio CEO Nikolay Semenov and Chandru Chawla, Head of Cipla New Ventures, signed the memorandum of understanding on technology transfer for manufacturing of anti-HIV drugs and drugs for hepatitis C treatment.
Subhanu Saxena, MD & global CEO, Cipla Ltd, said, “Currently there is no technology for full-cycle manufacturing of HIV treatment drugs in Russia. We are glad that, as a responsible partner together with Nacimbio we will be able to improve drug availability for patients and make our contribution to the fight against HIV.”
As a part of this agreement, Nacimbio, along with Cipla, will set up a facility in Russia to manufacture antiretroviral drugs. New drugs production will help to change therapeutic regimens and substantially increase availability of drugs for Russian patients. By 2019, total market share for anti-HIV drugs will increase to 60 percent.
“Today patients undergoing anti-HIV treatment have to take a lot of drugs every day. Our preparations will meet the expectations of Russian patients and will solve this problem. In 2017, we will finalise construction and validation of the manufacturing plant together with Cipla Ltd, products will be commercially available in 2018. Total investment in the project will be over Roubles 2.8 billion,” stated Nikolay Semenov, CEO, Nacimbio.
